Phio Pharmaceuticals wins patent allowances in the US, Canada and Japan

Phio Pharmaceuticals said it secured three notices of allowance and one grant decision for INTASYL compounds across the United States, Canada and Japan. The milestone expands the company’s intellectual property protection as it pushes its cancer-focused siRNA platform toward partnerships and eventual commercialization.

Why it matters: - The patent actions strengthen Phio Pharmaceuticals’ protection around its INTASYL siRNA platform in major markets. - Broader intellectual property coverage can support licensing talks, future partnerships and commercial plans. - The company’s portfolio now spans 54 issued patents covering INTASYL chemistry, gene targets, immuno-oncology compounds and therapeutic indications.

What happened: - Phio Pharmaceuticals announced multiple favorable patent actions for INTASYL compounds on July 17, 2026. - The company received three notices of allowance and one grant decision across the United States, Canada and Japan. - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company based in King of Prussia, Pennsylvania.

The details: - Phio Pharmaceuticals develops therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer. - The company said the new patent progress further strengthens its global intellectual property portfolio. - President and CEO Robert Bitterman said strong patent protection is an important part of the company’s strategy to advance immuno-oncology therapies and maximize the long-term value of the INTASYL platform. - Bitterman said the additional patent advancements across therapeutic areas and geographic regions will help strategic partnerships, support research and development, and eventual commercialization. - Phio Pharmaceuticals also noted that it is a B2i Digital Featured Company, with a profile available here. - The company’s lead clinical program is PH-762, an INTASYL compound that silences the PD-1 gene involved in multiple skin cancers. - The Phase 1b trial, NCT# 06014086, evaluated PH-762 for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. - Phio Pharmaceuticals says PH-762 is a potential non-surgical treatment for skin cancers. - The company’s website is phiopharma.com.

Between the lines: - The patent update does not change Phio’s clinical data, but it can improve the company’s bargaining position as it seeks outside support for development. - The emphasis on multiple geographies suggests Phio is trying to protect both the chemistry and commercial path for INTASYL in key markets. - The press release includes standard forward-looking language about FDA interactions, clinical timing, financing and commercialization, underscoring the execution risk still ahead.

What's next: - Phio Pharmaceuticals is expected to continue advancing PH-762 and related INTASYL programs while it builds on the newly allowed and granted patent claims. - The company says future FDA submissions and meetings are intended to clarify next steps in the PH-762 development program. - Phio Pharmaceuticals also says its current cash runway is expected to extend into the first half of 2027. - The company plans additional non-clinical toxicology work as part of its development path.

The bottom line: - Phio Pharmaceuticals is building a wider intellectual property moat around INTASYL as it tries to move its cancer program from development toward commercialization.